Korro to Present at the TD Cowen 46th Annual Health Care Conference Feb 25, 2026 04:05PM
Korro to Host Virtual Analyst Day on January 27, 2026 Jan 20, 2026 08:00AM
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference Jan 8, 2026 08:00AM
Korro Bio reports mixed results from KRRO-110 trial, cuts workforce by third Nov 12, 2025 04:52PM
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs Nov 12, 2025 04:05PM


Sep 2, 2025 04:30PM Korro to Participate in Upcoming Investor and Scientific Conferences
Aug 12, 2025 07:00AM Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
Jul 21, 2025 08:04AM Korro Bio receives European orphan drug designation for KRRO-110
Jul 21, 2025 08:00AM Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
May 14, 2025 04:05PM Korro to Participate in Upcoming Investor Conferences
May 7, 2025 04:30PM Korro Reports First Quarter 2025 Financial Results and Provides Business Updates
Apr 1, 2025 07:32AM Korro Bio (KRRO) Appoints Loïc Vincent as Chief Scientific Officer
Apr 1, 2025 07:30AM Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
Mar 18, 2025 07:00AM Korro Reports Full Year 2024 Financial Results and Provides Business Updates
Mar 14, 2025 08:01AM Korro Bio (KRRO): KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
Mar 14, 2025 08:00AM KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency